期刊
CIRCULATION RESEARCH
卷 117, 期 1, 页码 80-88出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCRESAHA.117.305365
关键词
cardiovascular diseases; cardiovascular disease modeling; induced pluripotent stem cells; myocytes; cardiac; precision medicine
资金
- National Institutes of Health (NIH) [R01 HL113006]
- NIH [R01 HL123968, R24 HL117756, K99 HL104002]
- California Institute of Regenerative Medicine [IT1-06596, DR2A-05394]
- AHA [15BGIA22730027]
- Stanford CVI Seed Grant
- Prince Mahidol Award Foundation, Thailand
Disease models are essential for understanding cardiovascular disease pathogenesis and developing new therapeutics. The human induced pluripotent stem cell (iPSC) technology has generated significant enthusiasm for its potential application in basic and translational cardiac research. Patient-specific iPSC-derived cardiomyocytes offer an attractive experimental platform to model cardiovascular diseases, study the earliest stages of human development, accelerate predictive drug toxicology tests, and advance potential regenerative therapies. Harnessing the power of iPSC-derived cardiomyocytes could eliminate confounding species-specific and interpersonal variations and ultimately pave the way for the development of personalized medicine for cardiovascular diseases. However, the predictive power of iPSC-derived cardiomyocytes as a valuable model is contingent on comprehensive and rigorous molecular and functional characterization.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据